What is ASND's five-year median EV/EBITDA?

There are not enough weekly readings yet for a five-year median EV/EBITDA.

Does a low historical rank mean a stock is a buy?

No. The rank compares ASND only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Ascendis Pharma A/S (ASND) valuation history

Health Care

$253.00

Latest weekly close · Market cap $16.6B

Ascendis Pharma's EV/EBITDA is unavailable because recent financial data is missing (as of Oct 30, 2026).

Forward P/E 25.3× (analyst estimates, not ranked).
No P/S: recent financial data is missing.
No EV/Sales: recent financial data is missing.

No EV/EBITDA chart for ASND right now

ASND has no weekly EV/EBITDA history to chart yet.

EV/EBITDA

n/mnot ranked

EV/EBITDA needs more weekly history to be ranked.

Growth, last 12 months vs the year before

Revenue: +115%
EPS: n/m

Health Care peers on EV/EBITDA

Each percentile compares a stock with its own last five years.

Compare ASND with peers

Health Care peers of ASND on EV/EBITDA
Stock	EV/EBITDA	Versus its own history	5-year percentile
ABBVAbbVie	23.0×	Above its usual range	89
AMGNAmgen	20.8×	Historically high	99
ARWRArrowhead Pharmaceuticals Inc	n/m	Not ranked	n/m, not ranked
BIIBBiogen	26.3×	Historically high	100
BMRNBioMarin Pharmaceutical Inc	48.0×	Within its usual range	40

Appears in

Sector: Health Care
Screens: Nuclear Stocks: Valuation Screen
Semiconductor Equipment Stocks: Valuation Screen

Screen Health Care stocks the same way

Research on ASND

No articles about ASND yet. How valuation percentiles work

Loading peers and related research…

About this history

What is ASND's current EV/EBITDA?: Ascendis Pharma's EV/EBITDA is unavailable because recent financial data is missing (as of Oct 30, 2026).
What is ASND's five-year median EV/EBITDA?: There are not enough weekly readings yet for a five-year median EV/EBITDA.
Does a low historical rank mean a stock is a buy?: No. The rank compares ASND only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.